ACE and COVID-19: Soon after the report of first clusters of COVID‐19 cases in China in December 2019, concerns were raised among clinicians and investigators that angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) might increase susceptibility to COVID‐19 infection and the likelihood of severe and fatal COVID‐19 illness.1